Wahlin A, Hörnsten P, Hedenus M, Malm C
Department of Medicine, University Hospital of Umeå, Sweden.
Cancer Chemother Pharmacol. 1991;28(6):480-3. doi: 10.1007/BF00685827.
A total of 44 adults aged 18-78 years were allocated to an open randomized study whose aim was to compare the efficacy and toxicity of mitoxantrone with those of daunorubicin in previously untreated patients presenting with acute myeloid leukemia. In one arm, induction treatment consisted of mitoxantrone plus cytarabine given on a 3- plus 7-day schedule. Post-induction treatment consisted of two courses of mitoxantrone plus cytarabine given on a 2- plus 5-day schedule. In the control arm, mitoxantrone was replaced by daunorubicin. In all, 14 of 21 eligible and evaluable patients in the mitoxantrone arm achieved a complete remission (CR). In the control arm, 14 of 20 subjects attained a CR. The median survival was 365 days for patients randomized to mitoxantrone-cytarabine and 401 days for those given daunorubicin-cytarabine. The efficacy and toxicity of mitoxantrone were similar to those of daunorubicin.
44名年龄在18至78岁的成年人被分配到一项开放性随机研究中，该研究旨在比较米托蒽醌与柔红霉素在初治急性髓系白血病患者中的疗效和毒性。在一组中，诱导治疗包括按3加7天方案给予米托蒽醌加阿糖胞苷。诱导后治疗包括按2加5天方案给予两个疗程的米托蒽醌加阿糖胞苷。在对照组中，米托蒽醌被柔红霉素替代。在米托蒽醌组的21名符合条件且可评估的患者中，共有14名实现了完全缓解（CR）。在对照组中，20名受试者中有14名达到CR。随机接受米托蒽醌-阿糖胞苷治疗的患者中位生存期为365天，接受柔红霉素-阿糖胞苷治疗的患者中位生存期为401天。米托蒽醌的疗效和毒性与柔红霉素相似。
